Atossa Therapeutics

Digital transformation in pharma is crucial, with 75% of organizations implementing Pharma 4.0. Key drivers include patient demands, regulatory changes, and competition. Top technologies include AI, IoT, blockchain, and digital twins. Strategic insights focus on R&D, supply chain, marketing, and patient engagement.

Atossa Therapeutics discovered compounds synergistic with (Z)-endoxifen for breast cancer treatment, targeting enzymes like MEK, PI3K, and AKT, enhancing cell death in MCF-7 cells. Presented at 2024 San Antonio Breast Cancer Symposium, suggesting potential for combination therapies.

Atossa Therapeutics announced three posters on (Z)-endoxifen pharmacokinetic and tolerability data from the Phase 2 EVANGELINE trial at SABCS 2024. The trial investigates (Z)-endoxifen as a neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer. Key findings include achieving target steady-state plasma concentrations, substantial tumor suppression, and well-tolerated (Z)-endoxifen. The trial is expected to proceed with an amended protocol in 2025.

Atossa Therapeutics presented Phase 2 EVANGELINE trial data at SABCS 2024, showing 50% of patients met target plasma concentrations with 80mg (Z)-endoxifen + goserelin, achieving tissue levels double plasma levels in 90% of patients. The treatment demonstrated substantial tumor suppression with Ki-67 response rates above 85% and was generally well-tolerated. EVANGELINE will proceed with an amended protocol comparing 40mg/day (Z)-endoxifen plus OFS to exemestane plus OFS, with recruitment starting in 2025.

Black Friday sale offers 20% off The Scenarionist Premium Annual Plan. Deep Tech Briefing #40 covers AI policy, startup funding, eVTOL sector challenges, AI standards, space tech advancements, protein AI innovation, energy scaling issues, and quantum computing progress.

Jason McCarthy of Maxim Group maintains a Buy rating on VistaGen Therapeutics (VTGN) with a $12.00 price target, citing successful Phase 3 trials for fasedienol in treating social anxiety disorder and a robust financial position with $97.6 million in cash reserves.

Actor James Van Der Beek and Rep. Gerry Connolly reveal cancer diagnoses. Omega-3 and omega-6 fatty acids linked to lower cancer risk. Alternatives to radiation therapy tattoos for breast cancer discussed. Lung cancer screening awareness low among high-risk individuals. Z-endoxifen reduces breast density in premenopausal women. Michelangelo possibly depicted breast cancer in Sistine Chapel. NCCN expands genetic risk assessment guidelines. Immunotherapy linked to myocarditis in some cancer patients. Pesticides may increase prostate cancer risk. Routine imaging after pancreatic cancer surgery prolongs survival. Tight sari skirts linked to 'petticoat' cancer. FDA approves MI Cancer Seek for targeted therapies. Cancer patients often visit ER before diagnosis.

(Z)-Endoxifen significantly reduced mammographic breast density in a Phase 2 study, potentially offering a new cancer prevention strategy.

Hexa-X II, led by Nokia, aims to evaluate 6G technology readiness, focusing on environmental sustainability, inclusion, and trustworthiness. The project includes 44 partners, such as Ericsson and Orange, to develop a pre-standardized 6G platform.